Last reviewed · How we verify
NCT01216267
Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples
NA trial testing Lansoprazole in Neuroendocrine Carcinoma (Carcinoid) in 200 participants. Completed in 1 January 2012.
1 January 2012
Quick facts
| Lead sponsor | University of Western Ontario, Canada |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 200 |
| Start date | 1 June 2010 |
| Primary completion | 1 January 2012 |
| Estimated completion | 1 January 2012 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Lansoprazole (lansoprazole) — full drug profile →
- lansoprazole (lansoprazole) — full drug profile →
Conditions studied
- Neuroendocrine Carcinoma (Carcinoid) — all drugs for Neuroendocrine Carcinoma (Carcinoid) →
Sponsor
University of Western Ontario, Canada
Who can join
Adults 18 to 70, any sex, with Neuroendocrine Carcinoma (Carcinoid). Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
chromogranin A concentration serum
Time frame: single time
For determination of normal CgA range, we will recruit 60 healthy subjects (30 female, 30 male), in whom a single plasma sample will be obtained for measurement of CgA B For determination of CgA in patients with carcinoid disease (active or inactaive), we wil recruit 200 patients with carcinoid disease from our local neuroendocinre oncology clinic.
Sponsor's own description
The goal of this study is to compare several methods for measurement of Chromogranin A in their ability to serve as a marker for disease activity in patients with neuroendocrine tumors. Further, in a subgroup, we will determine if taking a proton pump inhibitor affects Chromogranin A levels.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01216267
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lansoprazole
Trials testing the same drug.
- NCT06964334 — The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection · Phase 3 · not yet recruiting
- NCT06894992 — Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment · NA · recruiting
- NCT06931223 — Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia · NA · not yet recruiting
- NCT06284876 — Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer · Phase 3 · recruiting
- NCT04188119 — A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer · Phase 2 · withdrawn
Other University of Western Ontario, Canada trials
Trials by the same sponsor.
- NCT03743844 — Psychosocial Intervention for Women With Mood Disorders Seeking Treatment for Obesity · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01216267 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Western Ontario, Canada
- Last refreshed: 14 January 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01216267.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing